Navigation Links
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/2/2010

e treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C.  The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Form 10-Q for the quarter ended September 30, 2009.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statem
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
2. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
3. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
5. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
6. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
7. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
8. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... two upcoming investor conferences. On Tuesday, December ... Annual Piper Jaffray Healthcare Conference.  D. Keith ... an update on the company beginning at 11:30 a.m., ...
(Date:11/26/2014)... -- Cohen, Placitella & Roth, PC is investigating potential ... Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 2011 through November 2, 2014 ("Class Period").  The ... officers and directors publically disseminated materially false and/or ... 20(a) of the Securities Exchange Act of 1934 ...
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Avanir ... that the U.S. Food and Drug Administration (FDA) ... New Drug Application (NDA) for AVP-825. AVP-825 is ... sumatriptan powder delivered intranasally utilizing a novel Breath ... Complete Response letter, and consistent with the preliminary ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
... 15, 2011 PDI, Inc. (Nasdaq: ... promotional outsource services to established and emerging health care ... partnership with Qforma, the leading provider of advanced analytics ... Through this agreement, PDI will gain access ...
... REDWOOD CITY, Calif., March 15, 2011 – Ingenuity® ... solutions for life science researchers, today announced new ... in IPA®. Processed RNA-Seq datasets can now be ... context of pathways and diseases for a rich ...
Cached Medicine Technology:PDI Announces Exclusive Partnership With Qforma, Leading Provider of Advanced Analytics for Health Sciences Industry 2Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA 2Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA 3
(Date:11/27/2014)... (PRWEB) November 27, 2014 "As a ... embarrassing side effects of urinary incontinence," said an inventor ... and developed this specialized accessory to prevent leakage and ... Incontinence to absorb urine leakage. This prevents stains on ... potential embarrassment. The pad ensures that the individual has ...
(Date:11/27/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals ... eat a gluten-free diet, an expert says. Many ... potatoes and cranberry sauce -- are gluten-free, but "when ... may need to be considered," Dr. Anca Safta, director ... Wake Forest Baptist Medical Center in North Carolina, said ...
(Date:11/27/2014)... York (PRWEB) November 27, 2014 Tylenol ... who were allegedly injured by the medication are continuing ... federal litigation is looking ahead to a status conference ... to a Scheduling Order issued earlier this year, a ... December 16th at 10:00 a.m. Items likely to be ...
(Date:11/27/2014)... Developers and plugin specialist of Final Cut Pro ... FCPX to the next level. , “ProPip allows users to ... of a mouse,” said Christina Austin, CEO of Pixel Film ... appreciate.” , With ProPip users can show off their ... ProPip is great for commentaries, news casting, and more. PROPIP™ ...
(Date:11/27/2014)... to help with chores while they are home from school, ... self-esteem, and above all, helps parents maintain a somewhat tidy ... do you encourage your children to want to help? Is ... Development Journal, there is. The study found that adults’ language ... lend a hand. , The study found that using ...
Breaking Medicine News(10 mins):Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3
... Centers and free coffee ... give blood, DETROIT, Jan. 8 In honor of ... Cross Donors,Employees and Volunteers in Michigan for two weeks in ... all donors,at any of the participating American Red Cross blood ...
... among 19 countries when it comes to deaths that could ... care, according to new research supported by The Commonwealth Fund ... other nations dramatically improved these rates between 199798 and 200203, ... performed as well as the top three countries out of ...
... States places last among 19 countries when it comes ... to timely and effective health care, according to new ... the January/February issue of Health Affairs. While other nations ... U.S. improved only slightly. , If the U.S. had ...
... government intent on promoting innovation and fuelled by the ... abroad, Chinas health biotech industry only needs a more ... in the production of therapies and medicines both ... new study. , Long considered a skillful product replicator, ...
... for seniors underscore need for Congress to allow price,negotiation, ... 75 percent of Medicare drug plans continue to hike ... of $369 for five,commonly used drugs, between the month ... tracked increased prices on the five drugs by more ...
... NATICK, Mass., Jan. 7 Boston Scientific,Corporation (NYSE: ... for the,Federal Circuit affirmed a District Court ruling which ... patent owned by Johnson & Johnson.,The Appeals Court also ... invalid and affirmed the infringement of that claim. The ...
Cached Medicine News:Health News:Dunkin' Donuts Celebrates the New Year by Supplying Goodies to Michigan's American Red Cross 2Health News:New study: US ranks last among other industrialized nations on preventable deaths 2Health News:US ranks last among other industrialized nations on preventable deaths 2Health News:China's biotech industry: An Asian dragon is growing 2Health News:China's biotech industry: An Asian dragon is growing 3Health News:China's biotech industry: An Asian dragon is growing 4Health News:China's biotech industry: An Asian dragon is growing 5Health News:China's biotech industry: An Asian dragon is growing 6Health News:China's biotech industry: An Asian dragon is growing 7Health News:Most Medicare Drug Plans Continue to Hike Costs into 2008 Two-to-Three Times Rate of Inflation 2Health News:Most Medicare Drug Plans Continue to Hike Costs into 2008 Two-to-Three Times Rate of Inflation 3Health News:Boston Scientific Announces Court Decision 2
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
Medicine Products: